Overview

Methylphenidate in Childhood Apraxia of Speech

Status:
Not yet recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to describe the possible effects of methylphenidate (MPH) on speech intelligibility in children with childhood apraxia of speech (CAS) aged 6-12 years. This outcome will be compared between MPH intake and placebo intake.

Phase:

Phase 2

Details

Lead Sponsor:

Murdoch Childrens Research Institute

Treatments:

Methylphenidate